Investor mix
9 investors on record; lead investors include Wellington Partners Venture Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 22% |
| Private equity | 3 | 33% |
| Bank & private debt | 1 | 11% |
| Other / undisclosed | 3 | 33% |
Developer of immunotherapies to treat infectious diseases and cervical cancer using CyaA vector technology
9 investors on record; lead investors include Wellington Partners Venture Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 22% |
| Private equity | 3 | 33% |
| Bank & private debt | 1 | 11% |
| Other / undisclosed | 3 | 33% |